Roth Capital’s Bold Predictions: GeoVax Labs Q3 Earnings and Beyond
In a significant development for the biotech sector, Roth Capital has recently adjusted its third-quarter 2025 earnings per share (EPS) estimates for GeoVax Labs Inc. This revision…
In a significant development for the biotech sector, Roth Capital has recently adjusted its third-quarter 2025 earnings per share (EPS) estimates for GeoVax Labs Inc. This revision…